{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ependymomas&page=6", "query": { "condition": "Ependymomas", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 264, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ependymomas&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ependymomas&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T23:55:36.414Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003478", "title": "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "iodine I 131 monoclonal antibody 81C6", "type": "RADIATION" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "1997-10", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2013-02-20", "last_synced_at": "2026-10-26T23:55:36.414Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003478" }, { "nct_id": "NCT01024907", "title": "Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Brain Tumor", "Adult Brain Stem Glioma", "Adult Diffuse Astrocytoma", "Adult Ependymoma", "Adult Grade II Meningioma", "Adult Melanocytic Lesion", "Adult Meningeal Hemangiopericytoma", "Adult Mixed Glioma", "Adult Oligodendroglioma", "Adult Pineal Gland Astrocytoma", "Adult Pineocytoma", "Recurrent Adult Brain Tumor" ], "interventions": [ { "name": "proton beam radiation therapy", "type": "RADIATION" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "questionnaire administration", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2009-12-17", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2020-12-10", "last_synced_at": "2026-10-26T23:55:36.414Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01024907" }, { "nct_id": "NCT04732065", "title": "ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Midline Glioma (DMG)", "Glioblastoma", "Recurrent Ependymoma", "Recurrent Malignant Central Nervous System Neoplasm", "Spinal Cord Glioma", "World Health Organization (WHO) Grade III Glioma", "CNS Tumor", "Central Nervous System Tumor" ], "interventions": [ { "name": "ONC206", "type": "DRUG" }, { "name": "Standard of Care Radiation Therapy", "type": "RADIATION" }, { "name": "Optional Proton (1H) MR spectroscopy (MRS)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Sabine Mueller, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 208, "start_date": "2021-08-23", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-26T23:55:36.414Z", "location_count": 5, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04732065" }, { "nct_id": "NCT01478321", "title": "Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Ependymoma", "Adult Anaplastic Oligodendroglioma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "hypofractionated radiation therapy", "type": "RADIATION" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "questionnaire administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2011-12-14", "completion_date": "2018-09-12", "has_results": true, "last_update_posted_date": "2020-03-12", "last_synced_at": "2026-10-26T23:55:36.414Z", "location_count": 5, "location_summary": "Chicago, Illinois • Lake Forest, Illinois • Naperville, Illinois + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lake Forest", "state": "Illinois" }, { "city": "Naperville", "state": "Illinois" }, { "city": "Warrenville", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01478321" }, { "nct_id": "NCT03210714", "title": "Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Recurrent Childhood Ependymoma", "Recurrent Childhood Malignant Germ Cell Tumor", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Non-Hodgkin Lymphoma", "Recurrent Childhood Osteosarcoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Hepatoblastoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Glioma", "Recurrent Malignant Solid Neoplasm", "Recurrent Neuroblastoma", "Recurrent Primary Central Nervous System Neoplasm", "Recurrent Rhabdoid Tumor", "Refractory Childhood Malignant Germ Cell Tumor", "Refractory Childhood Osteosarcoma", "Refractory Childhood Rhabdomyosarcoma", "Refractory Childhood Soft Tissue Sarcoma", "Refractory Ependymoma", "Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Glioma", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Primary Central Nervous System Neoplasm", "Refractory Rhabdoid Tumor", "Wilms Tumor" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 20, "start_date": "2018-06-05", "completion_date": "2026-12-30", "has_results": true, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-26T23:55:36.414Z", "location_count": 114, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03210714" }, { "nct_id": "NCT00107458", "title": "Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "valproic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 26, "start_date": "2005-05", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2014-08-07", "last_synced_at": "2026-10-26T23:55:36.414Z", "location_count": 15, "location_summary": "Orange, California • Stanford, California • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00107458" }, { "nct_id": "NCT07664176", "title": "NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma", "High Grade Gliomas", "Medulloblastoma Recurrent", "Ependymoma Recurrent", "Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS", "Brain Tumor Recurrent" ], "interventions": [ { "name": "NeuroNavigation-Guided Focused Ultrasound (NgFUS)", "type": "DEVICE" }, { "name": "Lumason", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Children's National Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "3 Years to 25 Years" }, "enrollment_count": 30, "start_date": "2026-09", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-26T23:55:36.414Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07664176" }, { "nct_id": "NCT06521567", "title": "A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Hodgkin Lymphoma", "High and Low Grade Glioma", "Glioblastoma Multiforme (GBM)", "Diffuse Intrinsic Pontine Glioma (DIPG)", "Ependymoma", "Osteosarcoma", "Hepatic Tumors", "Hepatoblastoma", "Hepatocellular Carcinoma (HCC)", "Fibrolamellar Carcinoma", "Rhabdomyosarcoma" ], "interventions": [ { "name": "Cobolimab", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "0 Years to 21 Years" }, "enrollment_count": 83, "start_date": "2025-03-06", "completion_date": "2026-10-13", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-26T23:55:36.414Z", "location_count": 6, "location_summary": "Los Angeles, California • Iowa City, Iowa • Hackensack, New Jersey + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT06521567" }, { "nct_id": "NCT02859857", "title": "Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "BXQ-350", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 86, "start_date": "2016-09-01", "completion_date": "2020-06-15", "has_results": false, "last_update_posted_date": "2021-07-22", "last_synced_at": "2026-10-26T23:55:36.414Z", "location_count": 4, "location_summary": "Lexington, Kentucky • Albuquerque, New Mexico • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Lexington", "state": "Kentucky" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02859857" }, { "nct_id": "NCT01721577", "title": "Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma", "Gliosarcoma", "Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Anaplastic Oligoastrocytoma", "Anaplastic Ependymoma" ], "interventions": [ { "name": "AXL1717", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2012-12", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2023-05-22", "last_synced_at": "2026-10-26T23:55:36.414Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01721577" } ] }